Protein binding of salicylate in uremic and normal plasma
- PMID: 975718
- DOI: 10.1002/cpt1976204464
Protein binding of salicylate in uremic and normal plasma
Abstract
Protein binding of salicylate was studied by equilibrium dialysis at 37 degrees C in plasma from uremic patients and healthy subjects. The protein binding was considerably lower in the uremic plasma at all salicylate concentrations studied (14 to 1,400 mug/ml). Scatchard plots of the data were computer-analyzed assuming binding to the classes of binding sites. According to this analysis, the binding to the class of primary binding sites was considerably decreased in the uremic plasma. In addition to the effect of the uremic state, the binding was considerably decreased at high therapeutic plasma levels and at low albumin levels. The combined effect of two or three of these factors may lead to unexpectedly high unbound fractions of salicylate, which should be considered in the monitoring of plasma salicylate levels in patients.
Similar articles
-
Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.Clin Pharmacol Ther. 1980 May;27(5):628-35. doi: 10.1038/clpt.1980.89. Clin Pharmacol Ther. 1980. PMID: 7371361
-
Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.Clin Pharmacol Ther. 1976 Jul;20(1):36-47. doi: 10.1002/cpt197620136. Clin Pharmacol Ther. 1976. PMID: 1277724
-
Characterization of salicylate binding to synovial fluid and plasma protein in patients with rheumatoid arthritis.Eur J Clin Pharmacol. 1980 Nov;18(5):403-6. doi: 10.1007/BF00636793. Eur J Clin Pharmacol. 1980. PMID: 7439262
-
Plasma protein carbamylation and decreased acidic drug protein binding in uremia.Clin Pharmacol Ther. 1980 May;27(5):612-8. doi: 10.1038/clpt.1980.87. Clin Pharmacol Ther. 1980. PMID: 7371359
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.Eur J Clin Pharmacol. 1992;42(2):175-9. doi: 10.1007/BF00278480. Eur J Clin Pharmacol. 1992. PMID: 1618249
-
Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.J Pharmacokinet Biopharm. 1991 Oct;19(5):575-95. doi: 10.1007/BF01062964. J Pharmacokinet Biopharm. 1991. PMID: 1783992
-
Protein binding of tolfenamic acid in the plasma from patients with renal and hepatic disease.Eur J Clin Pharmacol. 1986;30(5):591-6. doi: 10.1007/BF00542420. Eur J Clin Pharmacol. 1986. PMID: 3758148
-
Correlation plasma levels, NSAID and therapeutic response.Clin Rheumatol. 1985 Jun;4(2):124-32. doi: 10.1007/BF02032282. Clin Rheumatol. 1985. PMID: 3891199 Review.
-
Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.Klin Wochenschr. 1983 Jul 1;61(13):649-53. doi: 10.1007/BF01487581. Klin Wochenschr. 1983. PMID: 6688447
MeSH terms
Substances
LinkOut - more resources
Molecular Biology Databases